Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF Return on Equity

Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF (GERM) currently reports a ROE of 4.32%. That is below the sector sector average of 11.3%. Use the charts on this page to explore Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF's ROE history and peer comparisons.

Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF's ROE of 4.32% is lower than the its sector sector average of 11.3%. That is roughly 61.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF's current 4.32% should be judged against industry norms (sector average: 11.3%) and against GERM's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 4.32%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 11.3%. From there, open related valuation or income-statement pages for Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF, and consider following GERM for alerts when major investors trade the stock.